Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 1/2 17Phase 1 15Phase 3 9Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 11Thoracic 2Sarcoma 2Endocrine 1Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 7pembrolizumab 5Ipilimumab 4Interferon alpha-2 3relatlimab 2Etoposide 2Drug Therapy 2Dacarbazine 2Cyclophosphamide 2sargramostim 1salicylhydroxamic acid 1pertuzumab 1peginterferon alfa-2b 1peginterferon alfa-2a 1molgramostim 1green tea extract polyphenone E 1fludarabine phosphate 1entrectinib 1cyclopropapyrroloindole 1cobimetinib 1atezolizumab 1Whole-Body Irradiation 1Vincristine 1Vemurafenib 1VAP-cyclo protocol 1Triamcinolone Acetonide 1Trastuzumab 1Thiotepa 1Temozolomide 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Temozolomide × Dermatologic × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡